SAN DIEGO--(BUSINESS WIRE)--Inocras, a leader in whole genome sequencing (WGS) and bioinformatics, has introduced MRDVision, a minimal residual disease (MRD) detection solution showcasing a limit of detection (LOD) down to one-in-a-million. MRDVision combines Inocras’s WGS cancer profiling platform, CancerVision, and Ultima Genomics’ ppmSeq™ technology to deliver high-accuracy detection of circulating tumor DNA. This assay offers a low limit of detection, straightforward workflow, and fast turnaround time, all at a low cost.
MRDVision sets a new standard in MRD testing by detecting circulating tumor DNA in patients’ blood after treatment, with a limit of detection (LOD) as low as one part-per-million. Unlike traditional approaches that rely on creating panels with a limited number of genes for each patient, Inocras’s whole genome-based approach identifies and tracks genetic markers across the entire genome. This approach enhances simplicity and increases efficiency while maintaining the high accuracy, with faster turnaround times and more data generated per assay. This data generated can also support a variety of research and discovery applications, including drug discovery and development.
MRDVision is powered by two advanced technologies: Inocras’s CancerVision and Ultima Genomics’ ppmSeq™ technology. CancerVision is a WGS cancer profiling platform with proprietary bioinformatics, offering highly sensitive mutation detection (> 99% sensitivity for SNV and Indel). It also captures copy number variations, structural variations, and mutations in non-coding areas with high precision. ppmSeq™ technology enables the detection of rare single nucleotide variants at the genome-wide scale with high sensitivity and low background error rates while preserving the workflow simplicity of a standard WGS-based MRD assay.
The results from MRDVision’s initial analytical validation will be presented at the American Society of Human Genetics (ASHG) annual meeting and at the Association for Molecular Pathology (AMP) annual meeting in November 2024. MRDVision is on track to be ready for clinical use by the end of 2024, with a commercial launch in early 2025.
"We are excited to introduce MRDVision as the first WGS-based MRD solution developed on Ultima's ppmSeq technology,” said Jehee Suh, CEO of Inocras. “MRDVision will be a game-changer in the field, providing groundbreaking sensitivity and genomic coverage, all while maintaining competitive economics and rapid turnaround times compared to widely used MRD products available today.”
"At Ultima, we developed our unique sequencing architecture to specifically meet the needs of large-scale applications by providing our customers extremely low limits of detection at high throughput and at low-cost," said Gilad Almogy, CEO of Ultima Genomics. "Our ppmSeq™ technology, with its extreme accuracy for SNVs, offers a significant opportunity to advance oncology testing, and we are excited to see Inocras utilize these key technology features in their development of their innovative approach to minimal residual disease testing."
About Inocras Inc:
Inocras is an AI-driven company that specializes in delivering critical insights to cancer and rare disease patients through whole genome sequencing and bioinformatics. The company offers its whole genome testing products, CancerVision and RareVision, and provides research services for pharmaceutical and biotechnology companies as well as research organizations through its CAP/CLIA lab, powered by its proprietary, IP-protected bioinformatics pipeline. Inocras is dedicated to unlocking the potential of whole genome data to enable precision health for everyone. For more information, please visit inocras.com and follow Inocras LinkedIn page
About Ultima Genomics:
Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit www.ultimagenomics.com.
